Objective: We aimed to assess the effect of APOE e variants on warfarin-related intracerebral hemorrhage (wICH), evaluated their predictive power, and tested for interaction with warfarin in causing wICH.
angiopathy (CAA), 7-9 a cerebral small vessel disease that accounts for 60% of lobar sICHs. 10 While wICH is generally considered to be mediated by the same vasculopathies that cause sICH, the specific role of APOE e variants in warfarin-exposed populations has not been extensively studied.
Genetic contribution is also important in warfarin metabolism. 11 Identification of APOE e as a risk factor for wICH could improve existing pharmacogenetic-based dosing algorithms 12, 13 for warfarin by adding information on subjects at increased risk of intracranial bleeding. Moreover, this genetic information could enhance existing risk stratification strategies, such as the CHADS 2 score, 14 that assist clinicians in the decision to start anticoagulation.
We aimed to establish to what extent previous results on APOE e and sICH are applicable to wICH specifically. We hypothesized that CAA is a strong contributor to lobar wICH, mirroring the pathologic process observed for lobar sICH, and that the combination of highrisk APOE e variants and warfarin treatment potentiate each other, resulting in higherthan-additive effects.
METHODS Study design. The discovery phase included data from the case-control Genetics of Cerebral Hemorrhage on Anticoagulation (GOCHA) Study, 15 a multicenter US study that includes the Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Mayo Clinic Jacksonville, and the Universities of Michigan, Virginia, Florida at Jacksonville, and Washington. Independent replication was undertaken in the case-control Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) Study, 16 at the University of Cincinnati, Ohio.
Standard protocol approvals, registrations, and patient consents. All studies were approved by the local institutional review board at each participating institution. Informed consent was obtained from all subjects, their legally authorized representatives, or waived via protocol-specific allowance for subjects who died during hospitalization.
Cases. Cases enrolled in both studies were subjects of selfreported European ancestry older than 55 years in GOCHA and older than 18 years in GERFHS. Cases were ascertained across participating studies using predefined standardized criteria. 6, 16 wICH was defined as a new and acute neurologic deficit in warfarin-exposed subjects with compatible findings in neuroimaging. Exclusion criteria included brain tumor, trauma, vascular malformation, hemorrhagic transformation of cerebral infarction, and any other cause of secondary ICH.
Imaging. wICH was confirmed by CT and categorized as lobar or nonlobar by stroke neurologists blinded to genotype data. wICH originating at the cortex and cortical-subcortical junction was categorized as lobar, and wICH selectively involving the basal ganglia, internal capsule, thalamus, deep periventricular white matter, cerebellum, and brainstem was categorized as nonlobar. Patients with multiple simultaneous hemorrhages involving both lobar and nonlobar regions were categorized as mixed ICH and excluded from the study (n 5 3). Individuals with CT images of poor quality that precluded location assignment were excluded (n 5 5). CAA status was evaluated by means of the Boston criteria. 17 Controls. Unmatched controls enrolled in both studies were subjects of self-reported European ancestry older than 55 years in GOCHA and older than 18 years in GERFHS. In the GOCHA Study, controls were ICH-free, warfarin-exposed subjects randomly sampled from ambulatory clinics at each participating study site. Warfarin-exposed controls were not available in the GERFHS Study, and study controls in this instance were ICHfree subjects sampled using random digit dialing. The distribution of APOE e variants was confirmed to be similar in warfarin-exposed and warfarin-unexposed controls (see below). In both studies, previous diagnoses of ICH, pre-enrollment dementia, or Alzheimer disease were rule out in controls through interview and revision of medical charts.
Genotyping. The 2 single nucleotide polymorphisms that define the e variants in APOE (rs7412 and rs429358) were genotyped utilizing 2 different direct genotyping methods. 18 The genotypes of rs7412 and rs429358 were used to determine APOE e status (e2e2, e3e3, e4e4, e3e2, e3e4, or e2e4). Research staff in charge of genotyping was blinded to neuroimaging and clinical data. Controls were confirmed to be in Hardy-Weinberg equilibrium for APOE genotypes. Differential missingness of APOE e variants across cases and controls was evaluated through x 2 tests. Genomewide genotyping was also performed in 379 GOCHA samples using Illumina HumanHap610-Quad (San Diego, CA), with subsequent implementation of standard quality-control procedures. 19 Statistical analysis. Hypothesis testing. Association analyses between APOE e genotypes and wICH were completed separately for lobar and nonlobar hemorrhages. Logistic regression models were fitted assuming independent additive genetic effects for e2 and e4 (1-df additive trend test for each), and adjusting for age, sex, and hypertension. Secondary analyses comprised inclusion of additional covariates in regression models (antiplatelet medications and vascular risk factors), and restriction of the replication sample to subjects older than 55 years, the latter seeking to mirror the inclusion criteria of the discovery study.
Population stratification. To account for population structure, principal component analysis 20 was implemented in the subset of GOCHA subjects with available genome-wide genotyping. Association testing in this subset of subjects was repeated as described above adding principal components 1 and 2 as covariates in the regression models.
Meta-analysis. Results from the discovery and replication phases were meta-analyzed using inverse-variance, fixed-effects meta-analysis. Heterogeneity was assessed by computing Cochrane Q (with corresponding p) and I 2 .
Genetic modeling. All available data were reanalyzed under dominant and recessive models. Differences in model fit between these modeling strategies and the additive approach were evaluated using likelihood ratio tests.
Predictive power. The overall contribution of APOE e genotype data to discrimination of case/control status was evaluated by computing receiver operating characteristic curves and corresponding C statistics for different models containing APOE information, after stratifying by ICH location. Fitted models included (1) age and sex, (2) age, sex, and APOE e, and (3) age, sex, vascular risk factors, and APOE e. Comparison of these models was performed using likelihood ratio tests.
Interaction analysis. Interaction between warfarin exposure and APOE e variants was assessed using a case-only approach, 21 in which the environmental exposure of interest was treated as the dependent variable and the genetic locus believed to interact with the environmental factor was tested as the independent variable.
All statistical analyses were completed using SAS 9.3 (SAS Institute Inc., Cary, NC). Quality-control processing of genome-wide data was implemented using PLINK 1.07. 22 Results were considered significant at Bonferroni-corrected p , 0.025 (2 tests for lobar and nonlobar wICH).
RESULTS
A total of 319 wICH cases (44% lobar and 56% nonlobar) and 355 controls were included in the discovery analysis (table 1). The majority of both cases (n 5 232, 73%) and controls (n 5 254, 72%) were receiving warfarin due to atrial fibrillation. A similar proportion of cases (18%) and controls (18%) were on infra-therapeutic levels of anticoagulation, as measured by an international normalized ratio (INR) ,2, but a significantly higher proportion of cases than controls were in upper levels of anticoagulation as defined by INR $3 (p , 0.001, figure 1 ). The GERFHS Study (replication stage) included 63 wICH cases (43% lobar and 57% nonlobar) and 1,030 controls in the full cohort, and 58 wICH cases (42% lobar and 58% nonlobar) and 699 controls when restricting to subjects older than 55 years (table 1) .
Lobar wICH. In the discovery stage, APOE e2 and e4 were significantly associated with lobar wICH (table 2) . After adjusting for age, sex, and hypertension, each additional e2 allele was associated with a 2.5-fold increase in risk of lobar wICH (odds ratio [OR] 2.46, 95% confidence interval [CI] 1.47-4.12; p , 0.001), whereas each additional e4 allele was associated with 2-fold increase in the same risk (OR 2.09, 95% CI 1.42-3.01; p , 0.001). These results remained unchanged when adjusting for several additional covariates (table e-1 on the Neurology ® Web site at Neurology.org). In this secondary analysis, age (p 5 0.007) and hypertension (p 5 0.004) were also associated with increased risk of lobar wICH, whereas hypercholesterolemia (p , 0.001) was associated with decreased risk (table e-1).
The associations described above were confirmed in the replication stage (table 3) for both e2 (OR 2.47, 95% CI 1.08-5.66; p 5 0.03; meta-analysis p 5 5.8 3 10 25 ) and e4 (OR 2.71, 95% CI 1.40-5.23; p 5 0.003; meta-analysis p 5 2.6 3 10 26 ). Similar results were obtained when restricting the replication sample to subjects older than 55 years (e2 p 5 0.05 and e4 p 5 0.03). The distribution of APOE e variants was similar in warfarin-exposed controls utilized in the discovery stage and in controls not exposed to warfarin included in the replication stage (e2 p 5 0.81 and e4 p 5 0.88). No heterogeneity was observed when pooling effect estimates across the discovery and replication stages for either e2 (Q p 5 0.99, I 2 5 0%) or e4 (Q p 5 0.51, I 2 5 0%). Evaluation for different modeling strategies confirmed that the assumption of additive genetic effects offered superior model fit over recessive (p , 0.001) or dominant (p , 0.001) models.
CAA-associated lobar wICH. The effect of e2 and e4 was stronger when the discovery sample of lobar wICH was restricted to definite/probable CAA cases, as defined by the Boston criteria. 17 Thirty-four of 141 lobar wICH . In this secondary analysis, age (p 5 0.003), hypertension (p 5 0.008), and diabetes (p 5 0.03) were also associated with increased risk of nonlobar wICH.
Replication results for e2 were consistent in the direction of the effect estimate but statistically nonsignificant (OR 1.41, 95% CI 0.64-3.07; p 5 0.45). Similar results were obtained when restricting the replication sample to subjects older than 55 years (e2 p 5 0.37). Meta-analysis results trended toward the Bonferronicorrected threshold for significance (OR 1.59, 95% CI 0.04-2.43; p 5 0.03; Q p 5 0.72, I 2 0%). As for lobar wICH, statistical modeling using additive genetics effects offered superior fit to the data when compared with recessive or dominant models (all p , 0.001).
Population stratification. Association results were reassessed after accounting for population structure. Genome-wide data were available in 190 cases and 189 controls included in the discovery stage. In this Discrimination of case/control status. Utilization of e2 and e4 genotype data in regression models improved discrimination between cases and controls for lobar but not for nonlobar wICH (figure 2). Taking models that included age and sex as the reference (M1 in figure 2 ), inclusion of e2 and e4 increased the C statistic of models with (M3 in figure 2 ; p 5 0.04) and without (M2 in figure 2 ; p , 0.001) vascular risk factors.
Interaction between warfarin and APOE status. No evidence of interaction between warfarin exposure and APOE status was found in the present analysis ( Post hoc power calculations. For each wICH type, assuming a 2-sided a 5 0.025, equal distribution of bleeding locations, and utilizing the allele frequencies and sample sizes described in table 1, the discovery stage had 80% power to detect ORs of 1.91 and 1.74 per each additional e2 and e4 allele, respectively. For the case-only interaction analysis, the study had 80% power to detect risk increments of 45% and 39% in subjects exposed to both warfarin and either e2 or e4 alleles, respectively.
DISCUSSION In this large, prospective, 2-stage (discovery and replication), case-control study assessing the role of APOE e variants in the occurrence of wICH, we demonstrated that APOE e2 and e4 represent strong risk factors for lobar wICH. Our results also suggest that this association is mediated by the effect of APOE e variants on CAA. No evidence of interaction between warfarin treatment and APOE was found, indicating that subjects carrying high-risk variants and receiving warfarin are exposed to additive increases in risk of sustaining wICH, but that these 2 exposures do not potentiate each other. Finally, these data provide preliminary evidence to support a role of APOE e genotype information in prediction models of wICH aimed to identify individuals at high risk of this condition. Our results confirm and extend previous reports on the role of APOE in lobar wICH. A previous small (32 lobar and 9 nonlobar wICH cases), unreplicated study found that APOE e2, but not e4, was overrepresented in subjects with CAA-related lobar wICH compared with ICH-free controls unexposed to warfarin. 23 In that study, e2 was associated with 3.8-fold increase in risk of lobar wICH. Our results support this previous communication by providing similar effect estimates in a larger sample size that included warfarin-exposed controls, independent replication, and convincing adjustment for population stratification. We also found evidence for a role of APOE e4 in risk of lobar wICH. While the study mentioned above did not find a relationship between e4 and wICH, 23 a large multicenter study on sICH found that each additional e4 allele was associated with a 2.2-fold increase in risk of lobar bleeding. 6 By showing location specificity for lobar hemorrhages and a significant association even when restricting the analysis to a small number of probable/possible CAA-related hemorrhages, our results extend the role of e4 to lobar wICH and highlight that CAA may represent an important biological mechanism for wICH. In general, these results support the notion that similar mechanisms may underlie the occurrence of wICH and sICH.
Our study did not find evidence of effect potentiation in subjects exposed to both warfarin treatment and high-risk APOE e variants. Interaction analysis involving these 2 risk factors is difficult because of a very low prevalence of warfarin exposure in the general population. To overcome this limitation, we implemented a case-only design, 21 in which the environmental exposure of interest becomes the dependent variable and the genetic locus believed to interact with the environmental factor is tested as the independent variable. This approach increases discovery power for gene-environment interactions in a variety of scenarios. 24 Further studies assessing the presence of biological interaction with different designs and statistical tools are needed to confirm our findings.
Genetic information on APOE e variants could have an important predictive role in 2 clinical settings: evaluation of the risk-benefit ratio of warfarin use in newly diagnosed cases of atrial fibrillation and specification of the optimal dosing scheme to achieve effective anticoagulation once warfarin is indicated. We have demonstrated that APOE e status improves the ability of regression models to discriminate lobar wICH cases and controls. These results must be interpreted with caution because they were derived from a case-control study design with a fixed exposure prevalence. Nonetheless, these data do provide important support to justify further evaluation of the predictive role of APOE e variants in wICH in properly designed cohort studies.
Several strengths of the present study contribute to the robustness our findings. All ICH cases were confirmed by neuroimaging and classified as lobar or nonlobar by expert neurologists and neuroradiologists, a crucial point given the biological heterogeneity underlying ICH in different locations of the brain. 25, 26 In addition, controls enrolled in the discovery stage of the study were also receiving warfarin, thus providing a more valid description of the distribution of exposure in the population that gave rise to the cases. Finally, both an independent replication and an appropriate strategy to account for population structure were implemented.
An important limitation of this study is that warfarin-exposed controls were only available in the discovery stage of the study. We address this issue by showing that the distribution of APOE genotypes in Receiver operating characteristic curves controls exposed and nonexposed to warfarin is similar. In addition, the clinic-based sampling technique for controls implemented in the discovery stage could have introduced selection bias because it would only capture warfarin-exposed individuals that are followed in ambulatory clinics. This bias is likely to be minor because the population of warfarin-exposed individuals that originated the cases requires routine follow-up in the ambulatory setting. Third, only one INR measurement per subject was available for analysis, providing only limited information on the overall temporal trend of each individual's response to warfarin. Fourth, the null results described for warfarin-APOE interaction analyses should be considered preliminary because of power limitations. Finally, these results were obtained in subjects of European ancestry and may not be applicable to other ethnicities. The results of this study indicate that both e2 and e4 variants in APOE are associated with increased risk of lobar wICH. Given the known relationship between these alleles and CAA, our results provide suggestive evidence for a role of this specific cerebral small vessel disease in causing lobar intraparenchymal bleeding in warfarin-exposed subjects. APOE genotype information improves case/control discrimination, which could justify future efforts to assess the predictive power of these genetic data. We did not find evidence of potentiation of effects in subjects exposed to both warfarin and high-risk APOE e variants. 
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